A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder

Pain

Volumn 119, Issue 1-3, 2005, Pages 5-15

  Arnold, Lesley M ^a   Rosen, Amy ^b   Pritchett, Yili Lu ^b   D'Souza, Deborah N ^b   Goldstein, David J ^c   Iyengar, Smriti ^b   Wernicke, Joachim F ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Duloxetine; Fibromyalgia; Randomized clinical trial

Indexed keywords

DULOXETINE; PLACEBO;

ADULT; ANOREXIA; APPETITE DISORDER; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBROMYALGIA; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MOOD; NAUSEA; NERVOUSNESS; OUTCOMES RESEARCH; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; XEROSTOMIA;

EID: 28644442626     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2005.06.031     Document Type: Article

References (31)

1. L.M. Arnold Systemic therapies for chronic pain D.J. Wallace D.J. Clauw Fibromyalgia and other central pain syndromes 2005 Lippincott/Williams, and Wilkins Philadelphia, PA 365 388
2. L.M. Arnold, P.E. Keck Jr, and J.A. Welge Antidepressant treatment of fibromyalgia. A meta-analysis and review Psychosomatics 41 2 2000 104 113
3. L.M. Arnold, Y. Lu, L.J. Crofford, M. Wohlreich, M.J. Detke, S. Iyengar, and D.J. Goldstein A double-blind, multicenter trial comparing duloxetine to placebo in the treatment of fibromyalgia patients with or without major depressive disorder Arthritis Rheum 50 9 2004 2974 2984
4. A.I. Basbaum, and H.L. Fields Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry Annu Rev Neurosci 7 1984 309 338
5. C.S. Burckhardt, S.R. Clark, and R.M. Bennett The fibromyalgia impact questionnaire: development and validation J Rheumatol 18 5 1991 728 733
6. F.M. Clark, and H.K. Proudfit The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: anatomical evidence that A5 neurons modulate nociception Brain Res 616 1-2 1993 200 210
7. C.S. Cleeland, and K.M. Ryan Pain assessment: global use of the brief pain inventory Ann Acad Med Singapore 23 2 1994 129 138
8. T.J. Coderre, and J. Katz Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain Behav Brain Sci 20 3 1997 404 419 [discussion p. 435-513]
9. A.A. Fischer Pressure threshold meter: its use for quantification of tender spots Arch Phys Med Rehabil 67 1986 836 838
10. D.J. Goldstein, Y. Lu, M.J. Detke, J. Hudson, S. Iyengar, and M.A. Demitrack Effects of duloxetine on painful physical symptoms associated with depression Psychosomatics 45 2004 17 28
11. L. Gormsen, A.R. Ribe, P. Raun, R. Rosenberg, P. Videbech, P. Vestergaard, F.W. Bach, and T.S. Jensen Pain thresholds during and after treatment of severe depression with electroconvulsive therapy Eur J Pain 8 2004 487 493
12. W. Guy ECDEU assessment manual for psychopharmacology, revised 1976 US Department of Health, Education, and Welfare publication (ADM). National Institute of Mental Health Rockville, MD p. 76-338
13. M. Hamilton A rating scale for depression J Neurol Neurosurg Psychiatry 23 1960 56 62
14. J.I. Hudson, and H.G. Pope Jr The relationship between fibromyalgia and major depressive disorder Rheum Dis Clin North Am 22 2 1996 285 303
15. 3H]imipramine reuptake in the primary fibromyalgia syndrome Rheumatology (Oxford) 40 3 2001 290 296
16. Y. Lu An application of path analysis in the design of clinical trails Proc Biopharm Section, Am Stat Assoc 2003 2576 2582
17. C.H. Mallinckrodt, W.S. Clark, and S.R. David Type I error rates from mixed-effects model repeated measures compared with fixed-effects ANOVA with missing values imputed via LOCF Drug Inf J 35 2001 1215 1225
18. S.P. McKenna, and S.M. Hunt A new measure of quality of life in depression: testing the reliability and construct validity of the QLDS Health Policy 22 3 1992 321 330
19. M.J. Millan Descending control of pain Prog Neurobiol 66 2002 355 474
20. L. Neumann, and D. Buskila Epidemiology of fibromyalgia Curr Pain Headache Rep 7 5 2003 362 368
21. P.G. O'Malley, E. Balden, G. Tomkins, J. Santoro, K. Kroenke, and J.L. Jackson Treatment of fibromyalgia with antidepressants: a meta-analysis J Gen Intern Med 15 9 2000 659 666
22. R.D. Retherford, and M.K. Choe Statistical models for Causal Analysis 1993 Wiley New York
23. I.J. Russell, H. Vaeroy, M. Javors, and F. Nyberg Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis Arthritis Rheum 35 5 1992 550 556
24. I.J. Russell, J.E. Michalek, G.A. Vipraio, E.M. Fletcher, M.A. Javors, and C.A. Bowden Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome J Rheumatol 19 1 1992 104 109
25. S. Schreiber, D. Shmueli, L. Grunhaus, O.T. Dolberg, E. Feldinger, F. Magora, and S.C. Shapira The influence of electroconvulsive therapy on pain threshold and pain tolerance in major depression patients before, during and after treatment Eur J Pain 7 2003 419 424
26. D.V. Sheehan, K. Harnett-Sheehan, and B.A. Raj The measurement of disability Int Clin Psychopharmacol 11 Suppl. 3 1996 89 95
27. J.E. Ware, K.K. Snow, M. Kosinski, and B. Gandek SF-36 health survey manual and interpretation guide 1993 The Health Institute, New England Medical Center Boston, MA
28. K.P. White, W.R. Nielson, M. Harth, T. Ostbye, and M. Speechley Chronic widespread musculoskeletal pain with or without fibromyalgia: psychological distress in a representative community adult sample J Rheumatol 29 3 2002 588 594
29. F. Wolfe, H.A. Smythe, M.B. Yunus, R.M. Bennett, C. Bombardier, D.L. Goldenberg, P. Tugwell, S.M. Campbell, M. Abeles, P. Clark, A.G. Fam, S.J. Farber, J.J. Fiechtner, C.M. Franklin, R.A. Gatter, D. Hamaty, J. Lessard, A.S. Lichtbroun, A.T. Masi, G.A. McCain, W.J. Reynolds, T.J. Romano, I.J. Russell, and R.P. Sheon The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee Arthritis Rheum 33 2 1990 160 172
30. F. Wolfe, K. Ross, J. Anderson, I.J. Russell, and L. Hebert The prevalence and characteristics of fibromyalgia in the general population Arthritis Rheum 38 1 1995 19 28
31. M.B. Yunus, J.W. Dailey, J.C. Aldag, A.T. Masi, and P.C. Jobe Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study J Rheumatol 19 1 1992 90 94